Literature DB >> 20110069

[Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema].

L Sillard1, T Passeron, N Cardot-Leccia, C Perrin, J-P Lacour, J-P Ortonne.   

Abstract

BACKGROUND: Scleromyxoedema is a rare disorder of unknown pathogenesis that is very difficult to treat. We report a case resistant to corticosteroid treatment but controlled by intravenous gammaglobulin (IVIG). CASE REPORT: A 60-year-old woman presented progressive generalized papular eruption with infiltrated and itchy lesions of between 2 and 5mm in diameter. Otherwise, the clinical examination was normal. Monoclonal gammopathy of the IgG lambda type was found. Histology confirmed the diagnosis of scleromyxoedema. The disease continued to progress despite oral corticosteroids (0.5mg/kg per day). Thalidomide was introduced but was discontinued after 2 months due to side effects. Treatment comprising six monthly infusions of IVIG (2g/kg on 5 days) resulted in a marked reduction (>50%) in lesions. Two months after discontinuation of IVIG, recurrence was observed and maintenance infusions of IVIG every 6 weeks were needed to control the disease. DISCUSSION: The course of scleromyxoedema is unpredictable and treatment is extremely difficult. Successful therapy with IGIV has been reported but this approach seems to afford only temporary relief and maintenance infusions are required, as confirmed by the initial efficacy of treatment in our patient and the rapid recurrence of lesions following withdrawal. Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20110069     DOI: 10.1016/j.annder.2009.11.010

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  2 in total

1.  [Scleromyxedema. A chronic progressive systemic disease].

Authors:  A Kreuter; M Stücker; A G A Kolios; P Altmeyer; K Möllenhoff
Journal:  Z Rheumatol       Date:  2012-08       Impact factor: 1.372

2.  Scleromyxedema: a case clinically and histologically responsive to intravenous immunoglobulin.

Authors:  Leslie Caudill; Eric Howell
Journal:  J Clin Aesthet Dermatol       Date:  2014-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.